Is Dr Agarwal's Hea overvalued or undervalued?
As of September 12, 2025, Dr Agarwal's Healthcare is considered very expensive with a PE ratio of 160.64, significantly higher than its peers, indicating it is overvalued despite slight recent stock outperformance against the Sensex.
As of 12 September 2025, the valuation grade for Dr Agarwal's Healthcare has moved from expensive to very expensive. The company is currently overvalued, with a PE ratio of 160.64, an EV to EBITDA of 31.07, and a Price to Book Value of 7.36. These metrics indicate that the stock is trading at a significant premium compared to its earnings and book value.In comparison to its peers, Dr Agarwal's Healthcare stands out with a notably higher PE ratio than Max Healthcare, which has a PE of 95.48, and Apollo Hospitals, which is at 71.91. The company's ROE of 4.58% and ROCE of 9.79% further suggest that it is not generating sufficient returns relative to its high valuation. Recent stock performance shows a slight outperformance against the Sensex over the past week, but the overall valuation remains concerning given the significant premium over its peers.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
